Asia-Pacific Cancer Diagnostics Market By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others), By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others), By End-User (Diagnostic Centers, Ho
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAsia-Pacific Cancer Diagnostics Market By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others), By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others), By End-User (Diagnostic Centers, Ho
Asia-Pacific cancer diagnostics market is expected to grow at impressive CAGR during the forecast period. The Asia-Pacific cancer diagnostics market is driven by rising prevalence of oncologic cases in the region. Moreover, increase in aging population is positively impacting the growth of market during the forecast period.
Additionally, growing requirement for effective screening tests coupled with new technology developments by leading companies are further expected to boost the growth of market over the forecast period. As with increasing ageing among the population will also lead to rising cases of cancer in upcoming years, thereby accounting for more demand across the region, thereby boosting the market growth in future.
Increasing Cancer Prevalence in the Region
Cancer is the second prevalent cause of death after cardiovascular diseases in the Asia-Pacific region. Common risk factors such as obesity, smoking, lack of exercise, excess sun exposure, as well as environmental exposures are the major factors contributing to up to 90-95 % of all cancer cases.
According to the Global Cancer Observatory Globocan 2020, Worldwide an estimation of 19.3 million new cancer cases, along with 10.0 million cancer deaths occurred in 2020. Breast cancer is the most commonly diagnosed cancer, surpassed the lung cancer as the most common cases with 2.3 million new cases (11.7%), followed by lung cancer (11.4), colorectal cancer (10%), prostate (7.3%), and stomach cancer (5.6%).According to Globocan 2020, approximately 58.3% of cancer deaths were estimated to occur in Asia in the year 2020, which is higher than the share of incidence (49.3%), due to the different distribution of cancer types and higher case fatality rates in the Asia-Pacific region.
Among these China, contributes to more than half of the world’s newly diagnosed liver and esophageal cancer cases, along with 42% newly diagnosed stomach cancer cases.
Growing Demand for Screening Tools and Techniques
Cancer being the most dreaded case among the population, diagnosing cancer at its earliest stages provides a best measure to get the appropriate treatment on time. For the early diagnosis distinct screening test and techniques are preferred to the patient at the earlier stage without even development of the symptoms. With the increasing incidence of cancer worldwide, early detection has become crucial in improving treatment outcomes and patient survival rates. This has led to the adoption of various screening methods, such as colonoscopy, mammography, and Pap smear, among others, to detect cancer at an early stage. The screening process is followed by diagnostic testing subjected to confirm the presence of cancer. Diagnostic testing includes various methods such as biopsies, imaging tests, and blood tests, etc., to determine the type, location, and stage of cancer. As a result, the growing demand for cancer screening is leading to an increased demand for diagnostic testing and cancer diagnosis. The cancer screening tests, as diagnoses the cancer at earlier stage also reduces the chance of death in the patient due to undergoing regular screening and followed treatment. Variety of medical organizations such as hospitals and clinics suggest distinct type of screening depending on the patient’s disease. Breast cancer screening, Cervical cancer screening Colorectal cancer screening, Lung cancer screening, Breast MRI, Prostate Cancer Screening, Multi-Cancer Detection tests, Prostate-specific antigen (PSA) blood test, Skin exams, virtual colonoscopy, etc. are some distinct type of Screening test and techniques for the diagnosis of cancer are thereby anticipating the market growth. Also, governments and healthcare organizations across the world are actively promoting cancer screening and diagnostic programs. Additionally, growing number of cancer diagnostics center and hospitals dedicated for the oncological treatment are rapidly growing in the region, thereby producing more opportunities for easy diagnostic, and thereby supporting the market growth in the forecast period.
Growth in Research & Development
According to Clinicaltrials.gov, 5213 clinical trials are in different phases of development across the globe for Colorectal Cancer
The national program such as National Cancer Institute (NCI) plans to improve, co-ordinate and fund resources and research diagnosis for the development of innovative diagnostic techniques of cancer and its assessment as it efficiently moves and introduces new scientific research and knowledge into practice and allowed improved novel diagnostic technologies and appropriate human specimens in order to efficiently characterize cancer.
Growing Demand for Precision Oncology
These treatments involve studying the genetic makeup and molecular pattern and characteristics of the cancer tumors in an individual patient. This novel approach is utilized to identify the changes in the genetic makeup ultimately by identifying the changes in the cells that might be causing the cancer to multiply and spread in the body. Through this precision oncology method personalized treatments can be developed and is of high importance in the diagnosis and treatment of a patient suffering cancer . Assitionally, precision treatment being highly targeted are efficient as they do not harm adjacent cells or healthy cells and thus have lesser side effect as a result.
Download Free Sample Report
Market Segmentation
Asia-Pacific cancer diagnostics market is segmented based on diagnostic type, technology, application, end-user, company, and region. Based on the Diagnostic Type, the market is segmented into Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing Biopsy and Others. Depending on the type of Technology, the market is segmented into IVD Testing, Imaging and Biopsy. Based on the Application type, the market is further segmented among Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin Cancer, and Others. Based on the By End-Users, the market is further segmented into, Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others.
Market Players
Thermo Fisher Scientific, Inc., GE Healthcare (A Subsidiary of General Electric Company), Abbott Laboratories, Inc., Becton, Dickinson and Company, Siemens AG, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Bio Rad Laboratories Inc., Illumina, Inc., Boehringer-Ingelheim International GmbH, and others are some of the major players operating in the Asia-Pacific cancer diagnostics market.
Major companies are developing advanced technologies and launching new products to stay competitive in the market. Other competitive strategies include mergers & acquisitions, partnerships, agreements, and new developments, in order to expand their geographic reach and to increase their customer base.
| Attribute | Details |
| Base Year | 2022 |
| Historic Data | 2018 – 2021 |
| Estimated Year | 2023 |
| Forecast Period | 2024 – 2028 |
| Quantitative Units | Revenue in USD Million and CAGR for 2018-2022 and 2023-2028 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Diagnostic Type · Technology · Application · End User |
| Country scope | China, India, Japan, South Korea, Australia, Singapore, Malaysia, Indonesia, Thailand & Philippines |
| Key companies profiled | Thermo Fisher Scientific, Inc., GE Healthcare (A Subsidiary of General Electric Company), Abbott Laboratories, Inc., Becton, Dickinson and Company, Siemens AG, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Bio Rad Laboratories Inc., Illumina, Inc., Boehringer-Ingelheim International GmbH. |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy